Brief: Cogent Biosciences Reports Recent Business Highlights And Second Quarter 2023 Financial Results
08/08/2023 14:05
Aug 8 (Reuters) - Cogent Biosciences Inc COGT.O :
* COGENT BIOSCIENCES REPORTS RECENT BUSINESS HIGHLIGHTS AND
SECOND
QUARTER 2023 FINANCIAL RESULTS
* ENDED 2Q 2023 WITH $350.9 MILLION, SUFFICIENT TO FUND
OPERATIONS
INTO 2026
* AS OF JUNE 30, 2023, CASH, CASH EQUIVALENTS AND MARKETABLE
SECURITIES WERE $350.9 MILLION
* QTRLY NET LOSS PER SHARE $0.59
* Q2 EARNINGS PER SHARE VIEW $-0.54 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX4j1D2B
Further company coverage: COGT.O
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's